First-in-human study to investigate the skin tolerability of micro-projection array patches coated with inactivated split influenza virus haemagglutinin (HA) from A/Singapore/GP1908/2015 (A/Michigan/45/2015(H1N1)-like) vaccine in healthy volunteers

Trial Profile

First-in-human study to investigate the skin tolerability of micro-projection array patches coated with inactivated split influenza virus haemagglutinin (HA) from A/Singapore/GP1908/2015 (A/Michigan/45/2015(H1N1)-like) vaccine in healthy volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Feb 2018

At a glance

  • Drugs Influenza-A-virus-H1N1-vaccines-Vaxxas (Primary) ; Influenza vaccine quadrivalent Seqirus
  • Indications Influenza virus infections
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Vaxxas
  • Most Recent Events

    • 20 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 02 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top